{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:14:40Z","timestamp":1751429680976,"version":"3.41.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["KAKENHI 20J40157"],"award-info":[{"award-number":["KAKENHI 20J40157"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020050","name":"Japan Intractable Diseases Research Foundation","doi-asserted-by":"publisher","award":["2019B01"],"award-info":[{"award-number":["2019B01"]}],"id":[{"id":"10.13039\/100020050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mishima Saiichi Memorial Foundation","award":["grant"],"award-info":[{"award-number":["grant"]}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","award":["grant"],"award-info":[{"award-number":["grant"]}],"id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","award":["grant"],"award-info":[{"award-number":["grant"]}],"id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bayer Academic Support","award":["grant"],"award-info":[{"award-number":["grant"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20ek0109333h0003"],"award-info":[{"award-number":["20ek0109333h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07341-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:51:12Z","timestamp":1751381472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post hoc analysis of a randomized placebo-controlled trial suggests potential visual benefits of branched-chain amino acids in retinitis pigmentosa"],"prefix":"10.1038","volume":"15","author":[{"given":"Tomoko","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanako Ohashi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Amino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harue","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitaka","family":"Tsujikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"7341_CR1","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","volume":"368","author":"DT Hartong","year":"2006","unstructured":"Hartong, D. T., Berson, E. L. & Dryja, T. P. Retinitis pigmentosa. Lancet. 368, 1795\u20131809 (2006).","journal-title":"Lancet"},{"key":"7341_CR2","unstructured":"O\u2019Neal, T. B. & Luther, E. E. Retinitis Pigmentosa. StatPearls. (StatPearls Publishing LLC, 2023)."},{"key":"7341_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","volume":"126","author":"AM Maguire","year":"2019","unstructured":"Maguire, A. M. et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in rpe65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology. 126, 1273\u20131285 (2019).","journal-title":"Ophthalmology"},{"key":"7341_CR4","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","volume":"26","author":"J Cehajic-Kapetanovic","year":"2020","unstructured":"Cehajic-Kapetanovic, J. et al. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat. Med. 26, 354\u2013359 (2020).","journal-title":"Nat. Med."},{"key":"7341_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00439-016-1637-y","volume":"135","author":"NG Ghazi","year":"2016","unstructured":"Ghazi, N. G. et al. Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial. Hum. Genet. 135, 327\u2013343 (2016).","journal-title":"Hum. Genet."},{"key":"7341_CR6","doi-asserted-by":"publisher","first-page":"e18228","DOI":"10.1016\/j.heliyon.2023.e18228","volume":"9","author":"B Li","year":"2023","unstructured":"Li, B. et al. Progress and prospects of gene therapy in ophthalmology from 2000 to 2022: a bibliometric analysis. Heliyon. 9, e18228 (2023).","journal-title":"Heliyon"},{"key":"7341_CR7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.4252\/wjsc.v13.i6.632","volume":"13","author":"G Mannino","year":"2021","unstructured":"Mannino, G. et al. Potential therapeutic applications of mesenchymal stem cells for the treatment of eye diseases. World J. Stem Cells. 13, 632\u2013644 (2021).","journal-title":"World J. Stem Cells"},{"key":"7341_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.reth.2022.12.005","volume":"22","author":"M Mandai","year":"2023","unstructured":"Mandai, M. Pluripotent stem cell-derived retinal organoid\/cells for retinal regeneration therapies: a review. Regener. Ther. 22, 59\u201367 (2023).","journal-title":"Regener. Ther."},{"key":"7341_CR9","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41591-021-01351-4","volume":"27","author":"JA Sahel","year":"2021","unstructured":"Sahel, J. A. et al. Partial recovery of visual function in a blind patient after optogenetic therapy. Nat. Med. 27, 1223\u20131229 (2021).","journal-title":"Nat. Med."},{"key":"7341_CR10","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/jamaophthalmol.2019.1476","volume":"137","author":"K Schaffrath","year":"2019","unstructured":"Schaffrath, K. et al. One-year safety and performance assessment of the Argus Ii retinal prosthesis: a postapproval study. JAMA Ophthalmol. 137, 896\u2013902 (2019).","journal-title":"JAMA Ophthalmol."},{"key":"7341_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ophtha.2017.09.019","volume":"125","author":"TL Edwards","year":"2018","unstructured":"Edwards, T. L. et al. Assessment of the electronic retinal implant alpha Ams in restoring vision to blind patients with end-stage retinitis pigmentosa. Ophthalmology. 125, 432\u2013443 (2018).","journal-title":"Ophthalmology"},{"key":"7341_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/archopht.1993.01090060049022","volume":"111","author":"EL Berson","year":"1993","unstructured":"Berson, E. L. et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch. Ophthalmol. 111, 761\u2013772 (1993).","journal-title":"Arch. Ophthalmol."},{"key":"7341_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1001\/archophthalmol.2010.32","volume":"128","author":"EL Berson","year":"2010","unstructured":"Berson, E. L. et al. Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch. Ophthalmol. 128, 403\u2013411 (2010).","journal-title":"Arch. Ophthalmol."},{"key":"7341_CR14","doi-asserted-by":"crossref","unstructured":"Birch, D. G., Bennett, L. D., Duncan, J. L., Weleber, R. G. & Pennesi, M. E. Long-term follow-up of patients with retinitis pigmentosa receiving intraocular ciliary neurotrophic factor implants. Am. J. Ophthalmol. 170, 10\u201314 (170).","DOI":"10.1016\/j.ajo.2016.07.013"},{"key":"7341_CR15","doi-asserted-by":"publisher","first-page":"6646","DOI":"10.1167\/iovs.15-17786","volume":"56","author":"DR Hoffman","year":"2015","unstructured":"Hoffman, D. R. et al. Docosahexaenoic acid slows visual field progression in X-linked retinitis pigmentosa: ancillary outcomes of the DHAX trial. Investig. Ophthalmol. Vis. Sci. 56, 6646\u20136653 (2015).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"7341_CR16","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1172\/JCI132990","volume":"130","author":"PA Campochiaro","year":"2020","unstructured":"Campochiaro, P. A. et al. Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial. J. Clin. Invest. 130, 1527\u20131541 (2020).","journal-title":"J. Clin. Invest."},{"key":"7341_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1023\/A:1019926122125","volume":"17","author":"H Pasantes-Morales","year":"2002","unstructured":"Pasantes-Morales, H., Quiroz, H. & Quesada, O. Treatment with taurine, diltiazem, and vitamin E retards the progressive visual field reduction in retinitis pigmentosa: a 3-year follow-up study. Metab. Brain Dis. 17, 183\u2013197 (2002).","journal-title":"Metab. Brain Dis."},{"key":"7341_CR18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaophthalmol.2018.1171","volume":"136","author":"DG Birch","year":"2018","unstructured":"Birch, D. G. et al. Effect of oral valproic acid vs placebo for vision loss in patients with autosomal dominant retinitis pigmentosa: a randomized phase 2 multicenter placebo-controlled clinical trial. JAMA Ophthalmol. 136, 849\u2013856 (2018).","journal-title":"JAMA Ophthalmol."},{"key":"7341_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000320500","volume":"225","author":"M Nakazawa","year":"2011","unstructured":"Nakazawa, M. et al. Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial. Ophthalmologica 225, 120\u2013126 (2011).","journal-title":"Ophthalmologica"},{"key":"7341_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40123-012-0005-9","volume":"1","author":"S Yamamoto","year":"2012","unstructured":"Yamamoto, S. et al. Topical isopropyl Unoprostone for retinitis pigmentosa: microperimetric results of the phase 2 clinical study. Ophthalmol. Ther. 1, 5 (2012).","journal-title":"Ophthalmol. Ther."},{"key":"7341_CR21","doi-asserted-by":"crossref","unstructured":"Sacchetti, M., Mantelli, F., Merlo, D. & Lambiase, A. Systematic review of randomized clinical trials on safety and efficacy of pharmacological and nonpharmacological treatments for retinitis pigmentosa. J. Ophthalmol. 2015, 737053 (2015).","DOI":"10.1155\/2015\/737053"},{"key":"7341_CR22","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.2147\/OPTH.S370032","volume":"16","author":"N Cross","year":"2022","unstructured":"Cross, N., van Steen, C., Zegaoui, Y., Satherley, A. & Angelillo, L. Current and future treatment of retinitis pigmentosa. Clin. Ophthalmol. 16, 2909\u20132921 (2022).","journal-title":"Clin. Ophthalmol."},{"key":"7341_CR23","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.1038\/srep05970","volume":"4","author":"HO Ikeda","year":"2014","unstructured":"Ikeda, H. O. et al. Novel VCP modulators mitigate major pathologies of rd10, a mouse model of retinitis pigmentosa. Sci. Rep. 4, 5970 (2014).","journal-title":"Sci. Rep."},{"key":"7341_CR24","doi-asserted-by":"publisher","first-page":"31184","DOI":"10.1038\/srep31184","volume":"6","author":"T Hasegawa","year":"2016","unstructured":"Hasegawa, T. et al. Neuoroprotective efficacies by KUS121, a VCP modulator, on animal models of retinal degeneration. Sci. Rep. 6, 31184 (2016).","journal-title":"Sci. Rep."},{"key":"7341_CR25","doi-asserted-by":"publisher","first-page":"44873","DOI":"10.1038\/srep44873","volume":"7","author":"M Hata","year":"2017","unstructured":"Hata, M. et al. KUS121, a VCP modulator, attenuates ischemic retinal cell death via suppressing endoplasmic reticulum stress. Sci. Rep. 7, 44873 (2017).","journal-title":"Sci. Rep."},{"key":"7341_CR26","doi-asserted-by":"publisher","first-page":"e0229068","DOI":"10.1371\/journal.pone.0229068","volume":"15","author":"HO Ikeda","year":"2020","unstructured":"Ikeda, H. O. et al. Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: an open-label, non-randomized, first-in-humans, phase 1\/2 trial. PLoS One. 15, e0229068 (2020).","journal-title":"PLoS One"},{"key":"7341_CR27","doi-asserted-by":"publisher","first-page":"e00096","DOI":"10.1016\/j.heliyon.2016.e00096","volume":"2","author":"N Nakano","year":"2016","unstructured":"Nakano, N. et al. Neuroprotective effects of VCP modulators in mouse models of glaucoma. Heliyon. 2, e00096 (2016).","journal-title":"Heliyon"},{"key":"7341_CR28","doi-asserted-by":"publisher","first-page":"e00624","DOI":"10.1016\/j.heliyon.2018.e00624","volume":"4","author":"Y Muraoka","year":"2018","unstructured":"Muraoka, Y. et al. KUS121, an ATP regulator, mitigates chorioretinal pathologies in animal models of age-related macular degeneration. Heliyon. 4, e00624 (2018).","journal-title":"Heliyon"},{"key":"7341_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1167\/iovs.63.9.7","volume":"63","author":"S Iwai","year":"2022","unstructured":"Iwai, S., Hasegawa, T., Ikeda, H. O. & Tsujikawa, A. Branched chain amino acids promote Atp production via translocation of glucose transporters. Investig. Ophthalmol. Vis. Sci. 63, 7 (2022).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"7341_CR30","doi-asserted-by":"publisher","first-page":"e00544","DOI":"10.1016\/j.heliyon.2018.e00544","volume":"4","author":"T Hasegawa","year":"2018","unstructured":"Hasegawa, T. et al. Branched chain amino acids attenuate major pathologies in mouse models of retinal degeneration and glaucoma. Heliyon. 4, e00544 (2018).","journal-title":"Heliyon"},{"key":"7341_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1167\/tvst.13.8.29","volume":"13","author":"HO Ikeda","year":"2024","unstructured":"Ikeda, H. O. et al. Efficacy and safety of branched chain amino acids on retinitis pigmentosa: A randomized, double-blind, placebo-controlled clinical trial. Transl. Vis. Sci. Technol. 13, 29 (2024).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"7341_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1167\/tvst.10.8.31","volume":"10","author":"T Hasegawa","year":"2021","unstructured":"Hasegawa, T. et al. Detection sensitivity of retinitis pigmentosa progression using static perimetry and optical coherence tomography. Transl. Vis. Sci. Technol. 10, 31 (2021).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"7341_CR33","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1167\/iovs.15-16704","volume":"56","author":"K Suda","year":"2015","unstructured":"Suda, K. et al. Comparison of longitudinal changes in functional and structural measures for evaluating progression of glaucomatous optic neuropathy. Investig. Ophthalmol. Vis. Sci. 56, 5477\u20135484 (2015).","journal-title":"Investig.. Ophthalmol. Vis. Sci."},{"key":"7341_CR34","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1001\/archopht.1984.01040030560017","volume":"102","author":"J Flammer","year":"1984","unstructured":"Flammer, J., Drance, S. M. & Zulauf, M. Differential light threshold. Short- and long-term fluctuation in patients with glaucoma, normal controls, and patients with suspected glaucoma. Arch. Ophthalmol. 102, 704\u2013706 (1984).","journal-title":"Arch. Ophthalmol."},{"key":"7341_CR35","doi-asserted-by":"publisher","first-page":"1114718","DOI":"10.3389\/fneur.2023.1114718","volume":"14","author":"MC Leitner","year":"2023","unstructured":"Leitner, M. C., Ladek, A. M., Hutzler, F., Reitsamer, H. & Hawelka, S. Placebo effect after visual restitution training: no eye-tracking controlled perimetric improvement after visual border stimulation in late subacute and chronic visual field defects after stroke. Front. Neurol. 14, 1114718 (2023).","journal-title":"Front. Neurol."},{"key":"7341_CR36","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1364\/BOE.2.001106","volume":"2","author":"DC Hood","year":"2011","unstructured":"Hood, D. C. et al. Method for deriving visual field boundaries from OCT scans of patients with retinitis pigmentosa. Biomed. Opt. Express. 2, 1106\u20131114 (2011).","journal-title":"Biomed. Opt. Express"},{"key":"7341_CR37","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1167\/iovs.18-24635","volume":"59","author":"A Sayo","year":"2018","unstructured":"Sayo, A. et al. Significant relationship of visual field sensitivity in central 10\u00b0 to thickness of retinal layers in retinitis pigmentosa. Investig. Ophthalmol. Vis. Sci. 59, 3469\u20133475 (2018).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"7341_CR38","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1167\/iovs.09-4945","volume":"51","author":"NV Rangaswamy","year":"2010","unstructured":"Rangaswamy, N. V., Patel, H. M., Locke, K. G., Hood, D. C. & Birch, D. G. A comparison of visual field sensitivity to photoreceptor thickness in retinitis pigmentosa. Investig. Ophthalmol. Vis. Sci. 51, 4213\u20134219 (2010).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"7341_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10633-012-9342-1","volume":"125","author":"CH Moon","year":"2012","unstructured":"Moon, C. H., Park, T. K. & Ohn, Y. H. Association between multifocal electroretinograms, optical coherence tomography and central visual sensitivity in advanced retinitis pigmentosa. Doc. Ophthalmol. 125, 113\u2013122 (2012).","journal-title":"Doc. Ophthalmol."},{"key":"7341_CR40","doi-asserted-by":"publisher","first-page":"22040","DOI":"10.1038\/s41598-023-49338-0","volume":"13","author":"Y Iga","year":"2023","unstructured":"Iga, Y. et al. Progression of retinitis pigmentosa on static perimetry, optical coherence tomography, and fundus autofluorescence. Sci. Rep. 13, 22040 (2023).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07341-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07341-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07341-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:51:15Z","timestamp":1751381475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07341-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7341"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07341-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.H. and H.I. were inventors of the studied drug patent (6764233 in Japan). The other authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20671"}}